Introduction: Prolonged intravenous infusion of beta-lactams increase the clinical cure rate compared to conventional administration in critical or septic patients. This study aimed to determine chemical stability and physical compatibility of meropenem at conditions used in clinical practice to evaluate the stability of the preparation during its administration and the possibility of anticipated preparation.
Methods: Admixtures in study were: (i) meropenem 6g in 0.9% sodium chloride (NS) in infusor of 2mL/h 50mL or 10mL/h 240mL; (ii) meropenem 1 or 2g in NS in infusion bag of 250mL. Temperatures of study were: (i) infusor: 4.5°C, 32°C or 12h at 4.5°C followed by 32°C; (ii) Infusion bag: 4.5°C, 24.5°C or 6h at 4.5°C followed by 24.5°C. Time of study was 5-6 days in infusor and 1 day in infusion bag. Chemical stability was evaluated by high performance liquid chromatography and physical compatibility by measuring pH and visual inspection.
Results: Chemical stability and physical compatibility of meropenem in admixtures in infusors were reduced at high meropenem concentration and high temperature. Admixtures in infusion bag show chemical stability and physical compatibility for at least 1 day.
Conclusion: Administration of meropenem 6g in infusion of 24h in 240mL of 0.9% NaCl in infusor of 10mL/h could be possible if the admixture is infused at 4.5°C. Extended infusion of meropenem 1 or 2g in 0.9% NaCl in infusion bag (250mL) in 3-4h is also feasible. Anticipated preparation of the admixtures in infusion bag is possible with a stability of 24h.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.eimce.2022.07.010 | DOI Listing |
Pain Ther
January 2025
Department of Anaesthesia, Tawam Hospital, PO Box 15258, Al Ain, United Arab Emirates.
Introduction: This review aimed to investigate the inadvertent administration of antibiotics via epidural and intrathecal routes. The secondary objective was to identify the contributing human and systemic factors.
Methods: PubMed, Scopus and Google Scholar databases were searched for the last five decades (1973-2023).
Trop Med Health
December 2024
School of Life Sciences, College of Agriculture, Engineering and Science, University of KwaZulu-Natal, Westville, 4001, South Africa.
Background: Sub-Saharan Africa faces one of the highest burdens of venereal diseases (VDs) globally. This review aims to critically evaluate the existing literature on the diverse Indigenous knowledge and medicinal plants utilised for treating VDs in sub-Saharan Africa.
Methods: We used the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) protocol to guide the execution of the review.
Hosp Pharm
December 2024
North Shore University Hospital, Manhasset, NY, USA.
Most antibiotics administered via intermittent IV infusion are diluted in 50 to 100 ml of diluent. The primary infusion set for the BD Alaris pumps can hold 25 ml of volume in its tubing, potentially contributing up to a 50% drug loss if residual volume is present after administration is complete. In the case of antibiotics, this may lead to significant underdosing, potentially contributing to reduced therapeutic response and emergence of antimicrobial resistance.
View Article and Find Full Text PDFDrugs
November 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Efgartigimod (Vyvgart; Vyvgart Hytrulo) is a neonatal fragment crystallizable receptor (FcRn) antagonist indicated for the treatment of generalised myasthenia gravis (gMG) in adults who are acetylcholine receptor (AChR) antibody positive (Ab+). Efgartigimod is approved for both intravenous (IV) and subcutaneous (SC) use. In a pivotal phase III trial, IV efgartigimod was associated with significant and clinically meaningful improvements in myasthenia gravis symptoms and reductions in disease burden.
View Article and Find Full Text PDFBrain Commun
October 2024
Department of Physiology, University of Auckland, Private Bag 92019, Auckland 1023, New Zealand.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!